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AbstrACt
Introduction The prevalence of attention deicit 
hyperactivity disorder (ADHD) within the Children and 
Young People Secure Estate (CYPSE) is much higher 
than seen in the general population. To make a diagnosis 
of ADHD, clinicians draw on information from multiple 
sources, including parents and teachers. However, 
obtaining these is particularly dificult for young people 
in the secure estate. There is increasing evidence in the 
community that QbTest is able to assist in the accurate 
and earlier diagnosis of ADHD. The objective of this study 
is to assess the feasibility and acceptability of QbTest in 
the assessment of ADHD within the CYPSE.
Methods and analysis A single- centre parallel group 
feasibility randomised controlled trial will be conducted. 
Sixty young people within the CYPSE identiied as 
displaying possible symptoms of ADHD will be randomised 
to the intervention arm (n=30; QbTest plus usual care) or 
control arm (n=30; usual care). Primary analyses will be 
descriptive and a process evaluation will be conducted 
to assess the contexts involved in implementing the 
intervention. Interviews will be conducted to explore 
acceptability and thematic analysis will be used to analyse 
the data.
Ethics and dissemination This study was approved by 
National Health Service Wales research ethics committee 
3 (18/WA/0347) on 15 February 2019. The indings will be 
published in peer- reviewed journals, presented at relevant 
conferences and disseminated to the public via summaries 
cocreated with our patient and public involvement group.
trial registration number ISRCTN17402196
IntroduCtIon
In England, children and young people aged 
10–17 years old remanded or sentenced into 
custody are placed in a variety of different 
secure establishments, known collectively 
as the Children and Young People Secure 
Estate (CYPSE). The CYPSE includes: Secure 
Children’s Homes, Secure Training Centres 
and Young Offenders Institutions (YOIs). 
The majority of young people are placed 
within the YOIs and there are four establish-
ments in England accepting 15–17 years old.
The prevalence rate of attention deficit 
hyperactivity disorder (ADHD) in the CYPSE 
is approximately 30%–40%, which is signifi-
cantly greater than the rate of 5%, seen in 
the general population.1 2 However, a report 
raised significant concerns about undetected 
neurodisability, including ADHD within 
the CYPSE, due to a lack of appropriate 
screening and assessment processes and 
training of staff.3 Additionally, many young 
people have comorbid mental health needs 
contributing to complexity in the assessment 
process. ADHD is associated with a range 
of poor outcomes, including a greater risk 
of developing other mental and physical 
health needs, educational and occupational 
problems and offending.4–13 The social and 
strengths and limitations of this study
 Ź This trial is novel as it is one of the irst trials within 
the Children and Young People Secure Estate.
 Ź Understanding the effects of context as barriers or 
facilitators is critical for interpreting the indings.
 Ź The study will engage meaningfully and substan-
tively with a patient and public involvement group to 
ensure that the research and intervention are both 
feasible and acceptable.
 Ź This is a feasibility trial and is not powered to show 
effectiveness of the intervention.
 Ź This feasibility trial is only being conducted in one 
site.
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economic burden of untreated ADHD on society is 
significant.14–19
The publication of the Healthcare Standards for Chil-
dren and Young People in Secure Settings20 attempted to 
provide a more standardised approach to the assessment 
and care provided within the CYPSE. One way was to 
recommend the use of the Comprehensive Health Assess-
ment Tool (CHAT).21 The CHAT was introduced into the 
CYPSE in 2013 and is completed within all CYPSE sites in 
England, UK. The CHAT is a semistructured assessment 
of health needs, delivered by a nurse during the first 10 
days of admission. If a nurse from talking with the young 
person and from observing them believes that they may 
have a need around difficulty concentrating, restlessness, 
fidgeting, and so on, then the nurse would recommend 
in the CHAT care plan that the young person be referred 
for a full ADHD assessment.
For a formal clinical diagnosis of ADHD, a key aspect is 
the use of information from informants such as parents, 
teachers and health professionals.6 7 However, access to 
such information can be difficult to obtain and take a long 
time to receive, resulting in delays to receiving a confirmed 
diagnosis. The number of days young people spend in the 
CYPSE is relatively short.22 Therefore, informant informa-
tion is very often not received before the young person 
leaves and returns back to the community. There is also 
evidence from a recent review within the CYPSE that estab-
lishments find it difficult to provide interventions to young 
people who are sentenced to fewer than 6 months, due to 
delays in assessment and/or diagnosis.23 All these factors 
can lead to delays in young people with ADHD receiving a 
diagnosis and accessing evidence- based treatment.
The impact of missed opportunities in diagnosis and 
accessing appropriate treatment can be significant. 
Young people with untreated ADHD in the CYPSE have 
been found to have an eightfold increased frequency 
of aggressive incidents in secure settings.24 25 Reducing 
violence and aggression is a key priority for Her Majes-
ty’s Prison & Probation Service and Ministry of Justice, 
given the increasing rates within prisons.26 Treatment of 
adult offenders with ADHD using medication has demon-
strated a reduction in reoffending of up to 41%.27 There-
fore, there are also likely social and economic benefits 
to improving the diagnosis and access to treatment for 
young people with ADHD in the CYPSE.
QbTest (Qbtech) is a computer task that measures 
three core aspects of ADHD: attention, impulsivity and 
motor activity. Performance on the task provides infor-
mation (via an immediate report) on the three symptom 
domains of ADHD and a ‘summary score’ based on devi-
ation from a normative data set based on age group and 
gender. QbTest can be used with individuals with mild 
learning disabilities as instructions on how to complete 
the task are visual. Practitioners use the information from 
the QbTest report in conjunction with the clinical infor-
mation (patient history, observation and ADHD symptom 
questionnaire) to inform their decision whether the 
young person has ADHD or not.
QbTest demonstrates good psychometric properties28 29 
and has the additional benefit over other computer tasks 
of measuring activity level, a core symptom of ADHD.30 
There are several studies that demonstrate the clin-
ical utility of QbTest in aiding diagnosis.31 32 A recent 
randomised controlled trial found clinicians with access 
to the QbTest report were more likely to reach a diag-
nostic decision about ADHD. At 6 months, 76% of those 
with a QbTest report had received a diagnostic decision, 
compared with 50% without a QbTest report. QbTest 
reduced appointment length, increased clinicians’ confi-
dence in their diagnostic decisions and doubled the like-
lihood of excluding ADHD.33
The use of the QbTest in the community looks prom-
ising.34 However, there are a number of unknowns in rela-
tion to its use in the CYPSE. Implementing new approaches 
can require more planning due to the regime; therefore, 
the potential barriers and facilitators to implementa-
tion need to be understood. The young people within 
the CYPSE are more complex and have greater comor-
bidity than young people accessing community Child and 
Adolescent Mental Health Services. The acceptability of 
the QbTest needs to be assessed to see if the same posi-
tive findings can be replicated. Primary outcomes in 
previous QbTest trials33 have been time to diagnosis, but 
given the comparative short stay in the CYPSE and diffi-
culty obtaining these data once they leave, it is unclear 
how reliably these data can be collected and/or if other 
outcomes, such as in aggressive incidents, are more 
important in this population.
The longer term aim is to undertake a definitive 
randomised controlled trial of the effectiveness of QbTest 
in the assessment of ADHD in the CYPSE. An evidence 
base within the CYPSE needs to be developed in order 
to change policy and implement the QbTest across the 
whole system. In line with the Medical Research Council 
(MRC) guidelines on developing complex interventions 
and as randomised controlled trials within the CYPSE are 
scarce, a feasibility study is required.35
trial objectives
To conduct a pragmatic feasibility randomised controlled 
trial to assess the feasibility and acceptability of QbTest in 
the assessment of ADHD within the CYPSE.
trial design
A parallel two- group randomised controlled trial with 1:1 
individual participant allocation to QbTest plus usual care 
(n=30; intervention group) or usual care alone (n=30; 
control group) with a parallel process evaluation. Recruit-
ment started in March 2019 and is due to last 12 months.
MEthods And AnAlysIs
setting
The study will be conducted in one YOI site within the 
CYPSE, in England.
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Eligibility criteria
Inclusion criteria
 Ź Identified as presenting with ADHD symptoms via the 
CHAT.
 Ź Aged 15–18 years old.
Exclusion criteria
 Ź On remand (uncertain/sudden release).
 Ź Non- English speaking (for pragmatic reasons, but 
will be included in the main trial testing applicability 
more widely).
 Ź Previous or current confirmed diagnosis of ADHD.
 Ź Currently receiving ADHD medication.
 Ź Deemed to present risk to either the researcher or the 
staff.
 Ź Unable to provide informed consent (over 16).
 Ź Parental/legal guardian consent not received (under 
16).
Potential participants will be identified by the prison 
healthcare team. The CHAT will identify potential 
participants displaying possible symptoms of ADHD, for 
example, any ADHD symptom codes in CHAT. Sentence 
status is accessible to healthcare staff via SystmOne 
(SystmOne is the clinical record system used within the 
CYPSE) and young people on remand will be excluded. 
Healthcare records will also be searched for previous or 
current confirmed diagnosis of ADHD and/or currently 
receiving ADHD medication and those young people 
will be excluded. The risk presented by potential partic-
ipants will be assessed by the healthcare team, based on 
knowledge of the young person, information contained 
on SystmOne and discussion with prison staff and will 
take account of the likely risk in prison and commu-
nity settings. Potential participants whose risk cannot be 
managed safely will be excluded.
usual care
The CHAT is a semistructured assessment of health 
needs. It is delivered by a nurse during the first 10 days 
of admission and includes assessing ADHD needs (not 
diagnostic) based on clinical history and observation of 
the young person. Young people identified with poten-
tial ADHD on the CHAT are discussed with the psychia-
trist at the multidisciplinary team. ADHD questionnaires 
(self, teacher and parent) are completed and reviewed. If 
further ADHD assessment is required, this includes clin-
ical assessment (history and observation) and obtaining 
informant information including developmental history 
(completed by nurse and psychiatrist). This typically 
involves a minimum of three appointments with the 
young person and liaison with teachers/parents.
Intervention: Qbtest plus usual care
Once the young person has been referred to the multi-
disciplinary team, the young person is booked into the 
QbTest clinic. The healthcare team will conduct the 
QbTest and use the information from the QbTest report 
in conjunction with the clinical information (patient 
history, observation and ADHD symptom questionnaire) 
to inform their decision whether the young person has 
ADHD or not. Young people randomised to the QbTest 
will receive usual care, as outlined above plus the QbTest. 
The QbTest takes approximately 20 min to complete and 
the results will be discussed with the psychiatrist and the 
young person; this will take approximately 10 min.
Primary outcomes
 Ź Eligibility rate recorded as the number of eligible 
young people against the total number of young 
people identified with ADHD needs.
 Ź Recruitment rate recorded as the number of eligible 
young people who consent to participate.
 Ź Acceptability of randomisation recorded as the 
number of young people randomised.
 Ź Acceptability of trial participation recorded as the 
number of eligible young people who drop out after 
receiving allocation.
 Ź Attrition rate recorded as the number of young 
people who consent to participate that remain in the 
study until the end of follow- up at 6 months.
secondary outcomes
 Ź Behaviour is measured using the Strengths and Diffi-
culties Questionnaire (SDQ)36 at baseline, 3 and 6 
months. The SDQ is a brief behavioural screening 
questionnaire. It contains 25 items divided between 
five scales: emotional symptoms; conduct problems; 
hyperactivity/inattention; peer relationship problems 
and prosocial behaviour. It takes 5–10 min to complete 
and is completed with the young person.
 Ź ADHD symptoms are measured using the Brief 
Barkley ADHD Rating Scale (B- BAARS)37 at baseline, 
3 and 6 months. The B- BAARS is a newly developed 
short (six item) screen for ADHD. It takes 5 min to 
complete and is completed with the young person.
 Ź Health- related quality of life is measured using the 
Child Health Utility Instrument38 at baseline, 3 and 6 
months. It takes 5 min to complete and is completed 
with the young person.
 Ź Objective rating of symptoms and functioning is 
measured by the Swanson, Nolan and Pelham Ques-
tionnaire (SNAP- IV 26)39 and Children’s Global 
Assessment Scale (C- GAS)40 at baseline, 3 and 6 
months. The SNAP- IV 26 screens for nine symptoms 
of ADHD hyperactive- impulsive type, nine symptoms 
of ADHD inattentive type and eight symptoms of 
oppositional defiant disorder as defined in the Diag-
nostic and Statistical Manual of Mental Disorders, 4th 
edition. The SNAP- IV is completed by a teacher within 
the CYPSE. The C- GAS is a 0–100 scale completed by 
a clinician which integrates psychological, social and 
academic functioning.
 Ź Number and duration of (in minutes) consultations/
appointments until confirmed ADHD diagnosis as 
recorded on a pro forma completed by clinicians after 
each consultation with the young person.
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 Ź Number of days until a confirmed diagnosis is reached 
using file information.
 Ź Contact with services is measured using the modi-
fied Client Service Receipt Inventory41 at baseline, 3 
and 6 months. It takes 5–10 min to complete and is 
completed with the young person.
 Ź Number of reordered behavioural incidents and adju-
dications are collecting using prison file information 
at baseline, 3 and 6 months.
sample size and recruitment
The required sample is 60 young people, 30 per study 
arm. This is large enough to test the feasibility of the 
research procedures and to establish a mean and SD 
on each outcome measure.42 Five young people are to 
be randomised into the study each month. Recruitment 
rates and the final target will be used to inform the deci-
sion to proceed to a definitive trial.
Attrition will be minimised by having robust trial 
procedures to prevent data loss. Procedures have been 
developed with our patient and public involvement 
(PPI) groups and tested for maintaining contact with 
participants. Recognising that this population can be 
difficult to follow- up, follow- up data collection points 
will occur within broad time windows. Having very 
broad time windows allows for as many follow- ups to be 
completed within the CYPSE, but also ensuring that no 
young people are excluded from the study if they miss a 
follow- up.
randomisation and blinding
Randomisation will be achieved by means of concealed 
random allocation conducted using an online pseudo-
random list hosted by  Sealedenvelope. com with random 
permuted blocks of varying sizes. Randomisation will be 
undertaken by the researcher, who will inform healthcare 
staff of trial arm allocation.
Given the nature of the intervention, it is not possible to 
blind participants or those involved in delivering the inter-
vention. It is also not possible to blind the field researcher 
due to the researcher and staff delivering the intervention 
working within the confines of a secure environment. It 
is also not possible to use a second researcher to collect 
follow- up data (who does not know trial arm allocation) as 
this is logistically very challenging and ultimately conflicts 
with the idea of building a strong researcher–participant 
relationship to enhance follow- up rates. Therefore, to 
minimise any potential bias, protocolising the collection 
of outcome measures which will be overseen by the onsite 
principal investigator and trial manager (CL). None of 
the outcome measures completed by the young person 
with the researcher present are particularly susceptible 
to bias as they are standardised, self- complete question-
naires. The researcher may need to support the young 
person in completing questionnaires due to literacy 
levels and protocolising collection ensures that support 
is consistent and unbiased. The study statistician (L- AC) 
will be blind to arm allocation.
Data collection
See table 1 for a summary of the study schedule of data 
collection.
Baseline data collection (t1)
The researcher will deliver the baseline data collection 
interview using a narrative conversational format. Demo-
graphics and questions from other measures are incor-
porated into a specially constructed flexible paper case 
report form which avoids duplication of subject matter in 
order to reduce disengagement or irritability.
Follow-up (t2–t3)
If the young person is to be released during the study, the 
researcher will meet with them usually within the week 
prior to release. During this meeting, the researcher will 
confirm the contact information provided at baseline and 
make any amendments to the information (eg, change 
of phone number). Once discharged, the researcher will 
contact the participant again in the community, to main-
tain engagement, confirm contact details and arrange the 
follow- up in the community.
The 3- month follow- up can take place between 61 and 
151 days post randomisation, although the researcher 
will endeavour to complete data collection as close to 
the 3- month (90- day) point. The 6- month follow- up can 
take place between 152 and 244 days postrandomisation, 
although the researcher will endeavour to complete data 
collection close to the 6- month point (182 days).
The follow- up may take place in prison or in the 
community, depending on if the young person has 
been discharged. In the community, the researcher will 
arrange to meet the young person at a convenient loca-
tion. Where possible, interviews will be conducted in the 
premises of services that the young person is engaged 
with in order to minimise risk to the researcher. Where 
this is not possible, the researcher will arrange to conduct 
the interviews in a suitable location in the community and 
adhere to the Local Lone Working Policy.
Process evaluation
QbTest in itself may not be defined as a complex inter-
vention requiring a process evaluation to understand the 
mechanisms of impact, for example, how QbTest produces 
change; however, delivering an intervention within a 
criminal justice setting is complex. Understanding the 
effects of the context as barriers or facilitators is critical 
for interpreting the findings and generalising beyond it 
to a full trial. The process evaluation will follow the MRC 
guidelines43 and will be conducted in parallel to the trial 
and will assess:
 Ź the acceptability of randomisation (interviews);
 Ź the acceptability of outcome measures (completeness 
of each measure and interviews);
 Ź the numbers of young people agreeing to sit the 
QbTest and the number who complete QbTest;
 Ź feedback from young people receiving the QbTest 
and health professionals using a questionnaire;
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Table 1 Summary of study schedule
Timepoint
Screening Baseline Allocation Follow- up
t0 t1 +3 mth t2 +6 mth t3
Enrolment:
  Eligibility screen X
  Informed consent X
  Parental consent (<16) X
  Allocation X
Interventions:
  Intervention group: QbTest   
Usual care   
  Control group: Usual care   
Assessments:
  Demographics X X
  SDQ X X
  B- BAARS X X
  CHU- 9D X X
  SNAP- IV X X
  C- GAS X X
  ADHD diagnosis and clinical conidence X
  Health records X X
  Prison records X X
  Modiied CSRI X X
  Contact sheet X X
Safety monitoring:
Adverse event reporting   
ADHD, attention deicit hyperactivity disorder; B- BAARS, Brief Barkley ADHD Rating Scale; C- GAS, Children's Global Assessment Scale; 
CHU- 9D, Child Health Utility Instrument; CSRI, Client Service Receipt Inventory; SDQ, Strengths and Dificulties Questionnaire; SNAP- IV, 
Swanson, Nolan and Pelham Questionnaire.
 Ź the acceptability of the QbTest via interviews with 
young people; and
 Ź health professionals and other CYPSE staff to obtain 
perspectives on facilitators and barriers to using the 
QbTest.
data collection
QbTest completion rates: a record will be taken of 
the numbers of participants who agree to sit and also 
complete the QbTest.
QbTest opinion questionnaire: all young people who 
receive QbTest will be asked to complete the QbTest 
opinion questionnaire at 3 months. The questionnaire 
contains 11 questions, for example, ‘the QbTest results 
were difficult to understand’ and the young person is 
asked to rate each item on a 5- point scale. At month 15, 
clinicians involved in the QbTest will be asked to complete 
the clinician version, which contains 13 questions rated 
on a 5- point scale and two free- text response questions.29
Interviews with young people: randomisation: a subsa-
mple of young people in both trial arms will be interviewed 
using a semistructured interview schedule to further 
explore acceptability of the randomisation process. 
Young person’s age and time of randomisation (begin-
ning or end of study) will be used to purposively select 
the sample. Outcomes: a subsample of young people in 
both trial arms will be interviewed using a semistructured 
interview schedule to further explore acceptability of 
completion of the outcome measures. Young person’s age 
and time of randomisation (beginning or end of study) 
will be used to purposively select the sample. QbTest: a 
subsample of young people who receive QbTest will be 
interviewed using a semistructured interview schedule 
to further explore acceptability of the QbTest and its 
administration as well as study processes and procedures. 
Scores/responses in the QbTest opinion questionnaire, 
young person’s age and whether or not the QbTest was 
completed will be used to purposively select the sample. 
Up to 20 young people will be interviewed.
Interviews with healthcare professionals and CYPSE 
staff: healthcare professionals and CYPSE staff will be 
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invited to participate in qualitative interviews to further 
explore acceptability and feasibility of administering and 
implementing the QbTest within usual assessment prac-
tices and procedures, including the barriers to its use 
and reasons for non- completion. Scores/responses in 
the QbTest Opinion Questionnaire will be used to purpo-
sively select healthcare professionals. Up to 10 profes-
sionals will be interviewed.
data analysis and management
Data analysis will be mainly descriptive.44 All measures 
will be summarised by group across follow- up time with 
mean and SD for normally distributed data, median for 
skewed variables and frequency (percentage) for categor-
ical data. All statistical analysis will be conducted using 
Stata V.15. No interim analysis is planned.
Interviews will be conducted and recorded by the 
researcher using an encrypted Dictaphone. All qualitative 
data will be analysed using thematic analysis45 with the 
aid of NVivo. Data will be coded inductively into themes, 
creating a detailed coding scheme, allowing for the inves-
tigation of emergent patterns between individual codes 
and boarder emergent themes.
Data will be double entered and stored on an encrypted 
and password- protected database at the University of 
Manchester. Double- entered data will be compared for 
discrepancies and discrepant data will be verified using 
the original paper data sheets (between LW- C and CL).
Monitoring
Adverse events
Serious adverse events (SAEs) will be recorded by the 
research team and reported to the chief investigator and 
Trial Steering Committee (TSC). Any SAEs deemed to 
have a causal relationship to trial participation will be 
reported to the sponsor within 24 hours of the chief inves-
tigator being informed.
Trial management and oversight
The TSC will oversee the conduct and safety of the 
trial and includes the role of the data monitoring. The 
committee includes an independent chair, independent 
members, a patient and public representative and the 
chief investigator. Representatives from both the sponsor 
and funding organisations will be invited to study- related 
elements of the TSC meetings as observers. The TSC will 
meet quarterly.
Audit
The trial coordinator or a nominated designee of the 
sponsor shall carry out monitoring of trial data as an 
ongoing activity. Trial data and evidence of monitoring 
and audits will be made available for inspection by the 
research ethics committee as required.
EthICs And dIssEMInAtIon
Health research authority approvals have been granted. 
Only the research team will have access to the study data, 
which will be stored in secure locked files or password- 
protected databases. Data will be available for inspec-
tion by the ethics committee on request. Changes to the 
protocol will be communicated to the ethics committee 
and trial registries by the trial manager (CL).
Consent process
Obtaining informed consent or assent will be in accor-
dance with ethical guidance and good clinical practice. 
The researcher will be trained to assess for capacity to 
consent in young people. This will include assessing if 
the young person has the ability to understand the infor-
mation relevant to the decision, retain the information, 
use or weigh the information as part of the process for 
decision- making and communicate the decision to the 
researcher.
The researcher will explain what participation in the 
study involves and how much time will be involved. They 
will also explain that participation is voluntary, that they 
can withdraw at any time and at any point and that their 
decision to participate, or not, will have no adverse 
effect on the care that they receive or their other legal 
rights. The researcher will also discuss the arrange-
ments in place to ensure confidentiality (and limits of 
this) and data protection. Throughout this process, 
the potential participant will be given an opportunity 
to ask questions. Potential participants will be made 
aware of circumstances in which confidentiality would 
be broken (if they or someone else identified may be at 
potential risk of harm; for example, self- harm, breaches 
of security and violence, including acts of terrorism/
radicalisation).
Having had the opportunity to discuss their involvement 
in the study and ask questions about it, potential partic-
ipants will be asked if they would like time (minimum 
24 hours) to consider taking part or if they would like 
to sign the consent form (online supplementary file 1—
consent form) if they are willing to take part.
Patient and Public Involvement
PPI significantly informs and impacts on this project. NB 
(coapplicant and coauthor) is the project PPI represen-
tative and is directly involved in the project providing 
her lived experience expertise throughout the project 
ensuring that the perspective of young people with ADHD 
and their parents are considered throughout. The project 
has PPI representatives from the community and also 
within the CYPSE and both groups have helped develop 
the information leaflets for the study and also helped 
develop and refine research procedures, for example, 
how best to explain what participation in the study 
involves and how best to achieve community follow- ups. 
The CYPSE PPI group meet with the researcher (LW- C) 
on a regular basis to feed into the project. The PPI groups 
will be involved in the analysis, reporting and dissemina-
tion of the research.
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dissemination
The findings from the trial will be used to inform the 
design, feasibility and acceptability of a future definitive 
trial. The findings will be published in peer- reviewed jour-
nals, presented at relevant conferences and disseminated 
to the public via summaries cocreated with our PPI group.
dIsCussIon
Secure settings are complex environments in which to 
conduct trials46 and there is a dearth of trials within the 
CYPSE. In the context of this challenging environment, a 
decision will be taken as to whether feasibility and accept-
ability are adequate for a full multicentre randomised 
controlled trial.
Current service provision for ADHD in the CYPSE is 
ad hoc and uncoordinated. There is growing evidence 
within community settings30 32–34 that QbTest has the 
potential to significantly improve the current assessment 
pathway having a direct impact on young people’s health, 
service delivery and criminal justice outcome.
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